Bleomycin Sulfate

製品コードS1214 別名：NSC125066

Bleomycin Sulfate化学構造

分子量(MW)：1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

サイズ 価格(税別)  
JPY 28220.00
JPY 111220.00
お問い合わせ バルク問合せ

文献中Selleckの製品使用例(6)

カスタマーフィードバック(1)

  • AACR 2011 Bleomycin Sulfate purchased from Selleck.

質量管理及び製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
体外試験

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 NUL3W206T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:w5qCUOTByMDFOwI0> NVrxVWRUOjRiaNMg MnTGbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MV:yOlA5QDdzMR?=
POLK WT NV2yOJFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fxc2lEPTB;MUGuO-KBkcLz4pEJNU44yqEQvF2= NU\IfWRzOjZyM{G0NFA>
POLK KO MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P4XWlEPTB;ND6wN-KBkcLz4pEJNU46OsLizszN MXyyOlA{OTRyMB?=
POLK CD NWW1T4lsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DWUGlEPTB;NT61PgKBkcLz4pEJNU4xOMLizszN MXSyOlA{OTRyMB?=
RLE/Abca3 NVXBeIxnTnWwY4Tpc44hSXO|YYm= MYGwMlTDqM7:TR?= MknJNVQ1yqCq MWLpcoR2[2W|IHGgcY9zeGixbH;nbYNidCClaHHu[4Uh\nKxbTDldIl1cGWuaXHsMYxqc2VibX;ydIhwdG:peTD0c{BiKHerZHWsJJNxemWjZD3veZQhdW:{cHjvcI9ogcLi MUGyOVc3ODV|OB?=
PMCs MWfGeY5kfGmxbjDBd5NigQ>? NXPnbZZuOC5z4pETNuKh|rypL33s MU[yOOKhcA>? M3KxcYNifXOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCycn;0[YlvKGyndnXsJI9nKGOxbHzh[4VvNUoEoB?= NWnyc|dNOjV3OUW2OFI>
PMCs NHflfFFHfW6ldHnvckBCe3OjeR?= NHfDeJExNjMEoN88[{9udA>? MVSyOQKBmzd{wrDo MkTZbY5lfWOnczDpcoNz\WG|ZYOgbY4hfmmvZX70bY4h[W6mIN8xMXNOSSCycn;0[Ylv MUOyOVU6PTZ2Mh?=
PMCs MlvESpVv[3Srb36gRZN{[Xl? NWKzUYRFOC5{wrFOwIcwdWx? NXrzNGtXPzJiaB?= MXfpcoR2[2W|IHTlZ5Jm[XOnczDpckBkgXSxa3XyZZRqdi16IHHu[EBGNWOjZHjldolvKHC{b4TlbY4> NYL3fHZDOjV3OUW2OFI>
PMCs M2qzeWZ2dmO2aX;uJGF{e2G7 M2D4NVAvOsLizsznM41t M3\S[lEzNzJ2L{S4JIg> M2fhbYlv[3KnYYPld{Bk\WyuIH3p[5JifGmxbh?= M4H5O|I2PTl3NkSy
IMR-32 M3OxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2juOlcvPeLKkkGyNEDDvWdxbXy= NUfZcnRyOTMkiKK0PEBp NVW5cVZJUUN3ME22NEDDvWdxbXygZZQhfGinIHXu[EBw\iB{NDDodpMhd2ZiaX7jeYJifGmxbh?= M4jZZlI2PTN4M{S1
HT1080 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\zNUDPxE1? MlfuNlQhcMLi MUHs[YFleyC2bzDhJGczN01iZHXsZZk> NY[4TmNlOjV3MUi5OlE>
HT1080 Mlj1SpVv[3Srb36gRZN{[Xl? MX6xJO69VQ>? NVLLWXVJOjRiaNMg NV\acGVTcW6mdXPld{BiKHCxdHXueEBodG:kYXygSG5CKGSjbXHn[UBz\XOyb37z[S=> M4nzT|I2PTF6OU[x
HDFn NEX2TYNEgXSxdH;4bYNqfHliQYPzZZk> Mn\YO|IhcA>? NIDXO2RKSzVyPUmuN|EmyqB? NULHZVhCOjV{N{[3PVI>
THP-1 MXjDfZRwfG:6aXPpeJkhSXO|YYm= MkD5O|IhcA>? MUnJR|UxRTRwN{el M1LQcVI2Ojd4N{my
HT-29 MX3DfZRwfG:6aXPpeJkhSXO|YYm= Mni0O|IhcA>? MkmzTWM2OD1zMT60PUU> M134fVI2Ojd4N{my
HCT116  M3;jfWN6fG:2b4jpZ4l1gSCDc4PhfS=> Moj6O|IhcA>? NHrCSoFKSzVyPUGxMlM1LQ>? MXOyOVI4Pjd7Mh?=
A431 NVLxNHRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HLWFUxNTJyMDDJWS=> MmLsOFjjiImq NE\rd3RqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NWjZdIpkOjVzMEGyPVk>
T24 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLNOVAuOjByIFnV Mm\iOFjjiImq NIX6O5hqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M1q0NlI2OTBzMkm5
AY-27  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojKOVAuOjByIFnV M2ja[FQ56oDLaB?= M17nO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NVTaXGJxOjVzMEGyPVk>
A549 NHixR2JHfW6ldHnvckBCe3OjeR?= NFjSOFMyKML3Zz;tUOKh M37mVVAuPDhiaB?= MX7pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> M1XQXFI1QTZ|NkO1
MLE12 NHPWXndHfW6ldHnvckBCe3OjeR?= MkDENUDDvWdxbV|CpC=> MUGwMVQ5KGh? M2XTb4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[uKhV1CQwrDtVm5C NVzTdm5KOjR7NkO2N|U>
Jurkat NVT6c5VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGyNQKBkc7:bR?= MVqyOQKBkWkEoB?= M1vRcoFzemW|dIOgeIhmKGOnbHygZ5lkdGViYYSgeIhmKEd{IIDoZZNm M1jWNlI1QTF4OEmz
HeLa  M4T6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorZTWM2OD1zMD6yxsDPxE1? M3fiXlI1PzN{M{m3
C18-4 NXPwV4M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPBNE0yODBizszN NVvaNpNScW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MlnHNlQ2PzF7OEK=
BMG-1  MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHZOFAwQDEEoN88[{9u NFzSW|Y{yqCq NIq4c2pqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NGX4OVAzOzlyNkeyOi=>
A459 M37jSmFxd3C2b4Ppd{BCe3OjeR?= MlyxNVAhdVV? NHrjNnk1QCCq MmLMbY5lfWOnczDhdI9xfG:|aYO= M3TmWlI{QTB{N{[2
MOCK M1z6NmFxd3C2b4Ppd{BCe3OjeR?= MX[xNEBuXQ>? MWO0PEBp NHr2bmFqdmS3Y3XzJIFxd3C2b4Ppdy=> MUiyN|kxOjd4Nh?=
MMP1 MXPBdI9xfG:|aYOgRZN{[Xl? MWmxNEBuXQ>? NVfEUYFRPDhiaB?= NWHi[HR6cW6mdXPld{BieG:ydH;zbZM> NIPybFIzOzlyMke2Oi=>
A549 M4LuZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmyNFAh|ryP NUHqeWdQOjRiaNMg M3z0fIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NGS3V|gzOzhyNUe5Ny=>
HCT-116 MnXyRZBweHSxc3nzJGF{e2G7 M3nG[lMwPy53L{G1JO69\y:vbB?= MoHlOFghcA>? MlLJdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> NHjaeWYzOzdyOE[2PC=>
HeLa MkK1RZBweHSxc3nzJGF{e2G7 M{\pZVMwPy53L{G1JO69\y:vbB?= NFfPS3I1QCCq NIrIXlhz\WS3Y3XzJJRp\SCuZY\lcEBw\iCETFigZZQhcGmpaDDjc45k\W62cnH0bY9v MnvwNlM4ODh4Nki=
HCT116 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXtd3FjOC1zMECg{txoN22u NF7ROlA1QCCq NH3UU4FqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MnToNlM2OTh{MEG=
NCM460 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOwMVExOCEQvHevcYw> M3Wxd|Q5KGh? MnrVbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NIe5Z3QzOzVzOEKwNS=>
NT2  M2DP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLEdYIzPCCqwrC= MYXMSFUxRTRyMPMAjeK2\y:vbB?= MnOyNlM{QDZ2MkC=
NT2  NEf3[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;pOFghcA>? MnHNUGQ2OD1zMECgxtVoN22u M1j6UVI{Ozh4NEKw
NT2  M{jQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHvXnN[PzJiaB?= NVTw[Yw3VER3ME2yNQKBkcL3Zz;tcC=> M{jNU|I{Ozh4NEKw
NT2  Ml32RZBweHSxc3nzJGF{e2G7 NYDQN5pQPDBy4pEJxtVoN22u MUWyOEBpyqB? NHrxfWVqdmS3Y3XzJJNq\26rZnnjZY51KGmwY4LlZZNmeyCrbjDjZZNx[XOnLUOsPEw6KGGldHn2bZR6yqB? NFjNb2czOzN6NkSyNC=>
NTera-2 NFz6cYZHfW6ldHnvckBCe3OjeR?= MmC5NVIxKM7:Zz;tcC=> MYe3NkBp Mnq2d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiOD3pd49xem:|dHHu[UBt\X[nbIO= MViyNlgzPTN3NR?=
NCCIT Mn;ESpVv[3Srb36gRZN{[Xl? MkD5NVIxKM7:Zz;tcC=> MnnjO|IhcA>? NF7heW9{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczC4MYl{d3C{b4P0ZY5mKGyndnXsdy=> NFfEOlQzOjh{NUO1OS=>
NTera-2 NX3uXZlwTnWwY4Tpc44hSXO|YYm= MnK4NVIxKM7:Zz;tcC=> MoDEO|IhcA>? NFrPOXV{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> M17He|IzQDJ3M{W1
NCCIT NGTSZ|FHfW6ldHnvckBCe3OjeR?= NFfaN2MyOjBizsznM41t MUK3NkBp MnvXd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiVFLBVnMhdGW4ZXzz NUK3UW1HOjJ6MkWzOVU>
NCCIT M2DDRmZ2dmO2aX;uJGF{e2G7 NVe4fXJPOTJyIN88[{9udA>? M4nkR|czKGh? M{PDTZNq\26rZnnjZY51dHliZHXjdoVie2W|IFfTTEBt\X[nbIO= MoLrNlI5OjV|NUW=
NTera-2 MlPTSpVv[3Srb36gRZN{[Xl? NVyzVpdUOTJyIN88[{9udA>? MYG3NkBp MkKxd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> MViyNlgzPTN3NR?=
NCCIT NXXyWW9vTnWwY4Tpc44hSXO|YYm= NVHhboN2OTJyIN88[{9udA>? MXG3NkBp NEi1XWZ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDQdo91\WmwIHPhdoJwdnmuIHzleoVtew>? NFi0T44zOjh{NUO1OS=>
NTera-2 NX;hZ20xTnWwY4Tpc44hSXO|YYm= MUmxNlAh|rypL33s NUDiTYttPzJiaB?= M4fjV5Nq\26rZnnjZY51dHliaX7jdoVie2W|IFzQU{Bt\X[nbIO= NX3E[HpSOjJ6MkWzOVU>
NCCIT NHLUNHhHfW6ldHnvckBCe3OjeR?= M4HjbVEzOCEQvHevcYw> MkDBO|IhcA>? MmW3d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiTGDPJIxmfmWucx?= MX6yNlgzPTN3NR?=
MDA-MB-468 NE\GVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XQ[VDjiJN{MEFCpO69\y:vTB?= NFzROHEzPCCq NWXiXHdwcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MYmyNlgyQTF7Nh?=
231-H2N M3zm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmw5qCUOjBywrFOwIcwdUx? MWGyOEBp Mlu5bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MlrYNlI5OTlzOU[=
A549  NIjkcYdHfW6ldHnvckBCe3OjeR?= Mmm0NlAxNzRyMDFOwG0> NWrTPGhCemW|dXz0d{BqdiCjIHTvd4UuemW|cH;ud4l3\SCrbnPy[YF{\SCrbjDSU3M> M36zTVIzPzd|Nkm3
A549  M{TkXGZ2dmO2aX;uJGF{e2G7 NFzBNVAxNTRyMDFOwG0> Ml\FNk01QCCq NXnMenBp[2G3c3XzJI1wemVibYTEUmEhfGijbjDuSG5CKGSjbXHn[S=> MYWyNlc4OzZ7Nx?=
A549  MUTGeY5kfGmxbjDBd5NigQ>? NEP1eo0yODBizszNxsA> MkXjNQKBmzR6IHi= MXrjZZV{\XNiY3HzdIF{\S1|IHHjeIl3[XSrb36= MkfWNlI4PzN4OUe=
A549  NIS5V2hHfW6ldHnvckBCe3OjeR?= MVexNFAh|ryPwrC= MXOw5qCUPDhiaB?= Mn\6Z4F2e2W|IGDLSFEh[2ynYY\h[4U> NGTBeWIzOjd5M{[5Oy=>
A549  NHPrcHNHfW6ldHnvckBCe3OjeR?= NGDZWpMyODBizszNxsA> NYXVNFFoOOLCk{S4JIg> M2\zPYNifXOnczDtbZRw[2ixbnTybYFtKGyxY3HsbZpifGmxbjDv[kBD[Xh? MnPXNlI4PzN4OUe=
A549  NVPpT|dvTnWwY4Tpc44hSXO|YYm= MlfGNVAxKM7:TdMg MmXNNQKBmzR6IHi= MYXk[YNz\WG|ZYOgUW1RKGGwZDDBWHAhdGW4ZXzz M2nVTlIzPzd|Nkm3
MCF-7/Her-18  Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3vZVRtOC52Mj2xO|AxKM7:Zz;tUC=> M1q2ZVI1KGh? MmPKbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MX2yNlYzOTRyNB?=
MCF-7 MmP3VGRVN1CFSTDUdoVifG2nboS= NXnuWZVROC5{NTFOwIcwdWxw MVyxMVQhcA>? NUTDN|Zse2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? MmWxNlI2QTF{OES=
MDA-MB-231 MWPQSHQwWEOLIGTy[YF1dWWwdB?= MUKwMlI2KM7:Zz;tcE4> MV2xMVQhcA>? MoDZd4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> MoDaNlI2QTF{OES=
MDA-MB-235  NVTvTYdtWESWL2DDTUBVemWjdH3lcpQ> MlnSNE4zPSEQvHevcYwv MkHrNU01KGh? NECxfYt{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 NXezOZhkOjJ3OUGyPFQ>
MCF-7 NWjndGVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLFdXExNTJizsznM41tNg>? M3TYelI1NzR6IHi= NVjQNJNmTUN3ME2xMlIh|rypL33M NHG0WWczOjV7MUK4OC=>
NCCIT  MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3veYQ3OjEkgKOxOFDDqM7:Zz;tcC=> NELhOZM4OiCq M{T4O2xFPTB;MUKwxsDPxGdxbX|CpC=> NWjqfJJ4OjJ3NkKxOlA>
NCCIT  MlvySpVv[3Srb36gRZN{[Xl? NFvRUFc4OiCq MXHzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTNiYXP0bZZqfHoEoB?= M1jtblIzPTZ{MU[w
NCCIT  M4P1b2Z2dmO2aX;uJGF{e2G7 NH7p[I84OiCq NEO3flR{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUigZYN1cX[rdIpCpC=> MmjONlI2PjJzNkC=
NCCIT  M4Tk[mZ2dmO2aX;uJGF{e2G7 MkfHO|IhcA>? NFrZUlB{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUmgZYN1cX[rdIpCpC=> M2DwOVIzPTZ{MU[w
NCCIT  M33oPGZ2dmO2aX;uJGF{e2G7 MYm3NkBp MULzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? NEP4WYczOjV4MkG2NC=>
NCCIT  MX;GeY5kfGmxbjDBd5NigQ>? MWK3NkBp NIP1OW1{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUhSmOuLUKgZ49vfGWwdB?= Ml3UNlI2PjJzNkC=
NCCIT  NYjJXXdKTnWwY4Tpc44hSXO|YYm= MkD5O|IhcA>? M1;6eZNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBEgXRvYzDs[ZZmdA>? MmrNNlI2PjJzNkC=
HeLa M3nTXWZ2dmO2aX;uJGF{e2G7 NGHVR4E{OC95MDFOwIcwdWx? NYLYVmtGOjUEoHi= M4q5eolv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqHB3M,-8kGFVVSyyMkJCpIFv\MLiR1HESFQ2 MXSyNlQ5Pzl|Nx?=
MCF-7  NY\MXJFyTnWwY4Tpc44hSXO|YYm= NWrI[oJROzBxN{Cg{txoN22u M{TxfFI1yqCq Mn\SbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKheDV|78{MRXRONHB{MdMgZY5lyqCJQVTEOFU> Mk\aNlI1QDd7M{e=
HeLa NHe2cpNEgXSxdH;4bYNqfHliQYPzZZk> M4i2VVMxNzdyIN88[{9udA>? M2n3S|I1yqCq M3y5Oolv\HWlZYOgbIlocGy7IIPp[45q\mmlYX70JIxmfmWuczDv[kBnemGpbXXueIVlKESQQTDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bR?= NX7zWGJOOjJ2OEe5N|c>
MCF-7  MWHDfZRwfG:6aXPpeJkhSXO|YYm= NVrQRVUyOzBxN{Cg{txoN22u NVjQb3k1OjUEoHi= NHTR[|RqdmS3Y3XzJIhq\2iueTDzbYdvcW[rY3HueEBt\X[nbIOgc4Yh\nKjZ33lcpRm\CCGTlGgdoVt\WG|ZTDpcpRwKHSqZTDjfZRweGyjc32= MmTVNlI1QDd7M{e=
NT2 Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPLNVAxNTZyMNMg{txoN22u M{nQPFI1KGh? NI[xdXVKSzVyPUSwNEDDvWdxbXy= MkflNlI1Pjl7NUK=
NT2 NV;uNYlYTnWwY4Tpc44hSXO|YYm= MXG0NFDDqM7:Zz;tcC=> M3;tUFI1KGh? NIrCR2t{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOsPEw6KGGldHn2bZR6yqB? NYTLTJN1OjJ2Nkm5OVI>
NT2 Mni0SpVv[3Srb36gRZN{[Xl? MUO0NFDDqM7:Zz;tcC=> MV:yOEBp M3T5VpNq\26rZnnjZY51dHliaX7jdoVie2W|IFLBXEBt\X[nbB?= M3ixTlIzPDZ7OUWy
NT2 NHrCOYlHfW6ldHnvckBCe3OjeR?= MUe0NFDDqM7:Zz;tcC=> NXH4UIFTOjRiaB?= NHT6coV{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDCZ4wuOiCuZY\lcC=> M{izcFIzPDZ7OUWy
CHO NW[4XJI5TnWwY4Tpc44hSXO|YYm= MmDJNk42yqEQvHevcYw> M1\iZ|E5KGhxNjDk NYXVbVZrcW6mdXPld:KheGW{c3nzeIVv[2Vib3[gZ4hzd22xc3;t[UBl[W2jZ3W= NGTkeZozOjJ|MEG5OS=>
Jurkat NFPyPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6wMVExOMLizsznM41t MV[yOEBp NUXZSIYy[XK{ZYP0d{B1cGViY3XscEBkgWOuZTDheEB1cGViR{KgdIhie2V? M1vhcVIzOjJ|M{Oy
Jurkat NWnSWphVTnWwY4Tpc44hSXO|YYm= M1XpUVMxyqEQvHevcYw> MVKyOEBp NXTFT3FncW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDjfYNtcW6|IFSzMEBCKGGwZDDCNS=> MknzNlIzOjN|M{K=
Jurkat MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XaWFAuOTBywrFOwIcwdWx? NXzsXlVjOjRiaB?= MXrpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKge4l1cCCjbjDJR|UxKH[jbIXlJI9nKDFyMN88[{9uVA>? Mn;jNlIzOjN|M{K=
Jurkat M{DNRWZ2dmO2aX;uJGF{e2G7 NED3[IU{OMLizsznM41t MWeyOEBp MWrpcoNz\WG|ZYOgeIhmKGWoZnXjeEBw\iCyeXPubYRqd26nIH;uJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNib3[gbIl{fG:wZTDINmEvYA>? NHfhTXYzOjJ{M{OzNi=>
U2OS EGFPnls MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH6NE0zyqEQvHevcYw> M1TVVVI1KGh? M{DVXolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M4LE[VIyQDFzMEC3
U2OS KuEnls M1zxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jpcFAuOsLizsznM41t M3S3VVI1KGh? NUHSeldvcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NGnLbWkzOThzMUCwOy=>
MCF-7 MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXiwcllHOC12MECg{txO MX[3NkBp NXLoUZRUVEN3ME2xOVEvQMLizszN NH7sSHAzOTdyM{K5NS=>
MCF-7/Adr  NHrMOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGCyZ3AxNTRyMDFOwG0> MYi3NkBp NVfPUpN6VEN3ME21PE42yqEQvF5CpC=> M{DHb|IyPzB|Mkmx
WI-38 NF7RdoJHfW6ldHnvckBCe3OjeR?= NU\mZlVzOC92MD:4NQKBkc7:Zz;tcOKh NHjxd2Q{KGh? NVvMOmxxcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? NUPqWGNGOjF3OUm2NVI>
hBMSC NFPRb4FHfW6ldHnvckBCe3OjeR?= MkDmNE81OC96MPMAje69\y:vbNMg NYfUeFdHOyCq NGfYOnZqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh NFvwVnozOTV7OU[xNi=>
NCI-H23 NHHtfHNHfW6ldHnvckBCe3OjeR?= M1vyeVAwPDBxOEFihKnPxGdxbX|CpC=> M{PDZVMhcA>? M2rneIlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NHW2NnMzOTV7OU[xNi=>
A-549 MVvGeY5kfGmxbjDBd5NigQ>? M{PmZlAwPDBxOEFihKnPxGdxbX|CpC=> NGLoUXU{KGh? M3\jdIlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> M33zPFIyPTl7NkGy
PBL  NE\lNo5HfW6ldHnvckBCe3OjeR?= M{jY[|AwPDBxOEFihKnPxGdxbX|CpC=> MlvRN{Bp NI\rd2JqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh MXGyNVU6QTZzMh?=
pol β −/− MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjGXIVlOC5{NT2yNFDDqM7:Zz;tcC=> NWTIZnNzOjUEoHi= NFLMbnVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? NWDk[pgzOjF{NUG5OFQ>
pol β +/+ NGLkWHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rsZ|AvOjVvMkCwxsDPxGdxbXy= NIDDWGkzPMLiaB?= MVLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3n0bEBqdmO{ZXHzbY5oKGOxbnPlcpRz[XSrb37zxsA> NVnwcXRlOjF{NUG5OFQ>
pol β −/− M1zhNmZ2dmO2aX;uJGF{e2G7 MkHoNE0zNjVizsznM41t MnHQNkBp M2C0S4NifXOnczDEUmEh\GGvYXfl MkXBNlEzPTF7NES=
pol β +/+ M1fCfGZ2dmO2aX;uJGF{e2G7 MorXNE0zNjVizsznM41t MXqyJIg> Mkm4Z4F2e2W|IFTORUBl[W2jZ3W= MXSyNVI2OTl2NB?=
pol β −/− M4DVWGZ2dmO2aX;uJGF{e2G7 M2DsSFAuPSEQvHevcYw> NEnpfYs1QCCq M{mxZoNifXOnczDtbYNzd263Y3zleZMh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MWqyNVI2OTl2NB?=
pol β +/+ M1OySmZ2dmO2aX;uJGF{e2G7 NV;sR4J[OC13IN88[{9udA>? MVO0PEBp M2XOeYNifXOnczDtbYNzd263Y3zleZMh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> NXe1XXBNOjF{NUG5OFQ>
TK6  NYLETVdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4OwRlI2NTF3MDFOwIcwdWx? NF;FXXA6PiCq M1f3O4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NXHuWHUxOjFyOEG0PFc>
TK6  sLUC+Apn1 NYOwUpVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K2c|I2NTF3MDFOwIcwdWx? M2e2Nlk3KGh? MWTpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MoXxNlExQDF2OEe=
TK6 sAPE1+Apn1 NIXYO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWO1dVFVOjVvMUWwJO69\y:vbB?= M1XCO|k3KGh? MnrKd4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7 NF24N5czOTB6MUS4Oy=>
HCT116 M2LWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzhNlUuOTVyIN88[{9udA>? NEDlbW06PiCq MnfrbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MkfINlExQDF2OEe=
HCT116 sLUC+Apn1 M3juTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i4Z|I2NTF3MDFOwIcwdWx? NXLtTnBsQTZiaB?= M1HVTolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NWjqUmEyOjFyOEG0PFc>
HCT116 sAPE1+Apn1 M4H2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPkXYIzPS1zNUCg{txoN22u NVLHVJpFQTZiaB?= M2nRR5Nq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= MVOyNVA5OTR6Nx?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい
体内試験 Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

お薦めの試験操作（参考用のみ）

細胞試験：

[4]
+ 展開
  • 細胞株： ADIPO-P2 cells
  • 濃度： 2.5 μg/mL
  • 反応時間： 30 minutes
  • 実験の流れ：

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (参考用のみ)
動物試験：

[7]
+ 展開
  • 動物モデル： CD-1 mice
  • 製剤： Saline
  • 投薬量： 5 mg/kg, 2 ml/kg
  • 投与方法： Administered via i.t.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (66.11 mM) warming
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
体内 左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
Saline
混合させたのち直ちに使用することを推奨します。 		30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 1512.62
化学式

C55H85N17O25S4
CAS No. 9041-93-4
保管 粉
in solvent
別名 NSC125066

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03596918 Recruiting AIDS-Related Kaposi Sarcoma|Human Immunodeficiency Virus 1 Positive AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California Los Angeles October 10 2018 Phase 1
NCT02166463 Recruiting Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma National Cancer Institute (NCI) March 16 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Children''s Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01132807 Completed Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 8 2010 Phase 2
NCT01026220 Completed Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Children''s Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • 回答：

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

selleck catalog

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • YK-4-279

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • BMH-21

    BMH-21 is a DNA intercalator, which binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription.

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Gemcitabine

    Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

Tags: Bleomycin Sulfateを買う | Bleomycin Sulfate ic50 | Bleomycin Sulfate供給者 | Bleomycin Sulfateを購入する | Bleomycin Sulfate費用 | Bleomycin Sulfate生産者 | オーダーBleomycin Sulfate | Bleomycin Sulfate化学構造 | Bleomycin Sulfate分子量 | Bleomycin Sulfate代理店
×

平素は、格別のご愛顧を賜り厚く御礼申し上げます。
誠に勝手ながら、弊社では下記の期間を年末年始による休業とさせていただきます。
【休業期間】
2018年12月29日(土)から2019年1月6日(日)
休業期間中にいただきましたお問合せ等につきましては、2019年1月7日(月)以降の対応とさせていただきます。また、年内の出荷業務は2018年12月26日(水)までとさせていただきます。
ご不便をお掛けいたしますが、ご了承のほど何卒よろしくお願いいたします。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID